葡萄糖-6-酸盐脱酶缺乏促进了肝炎E病毒的进入,并加剧了肝损伤
Dongxue Chen1, Xiaoxia Hu1, Yuanwen Xue1
1Medical School, The Academy for Cells and Life Health, Kunming University of Science and Technology, Kunming, PR China.
Virology journal
|December 18, 2025
概括
患有葡萄糖-6-酸盐脱酶 (G6PD) 缺乏症的患者更容易感染肝炎E病毒 (HEV). 缺乏G6PD有助于HEV进入并增加疾病的严重程度,可能是由于氧化应激.
科学领域:
- 肝病学和病毒学.
- 酶缺乏症 酶缺乏症
- 传染性疾病 传染性疾病
背景情况:
- 葡萄糖-6-酸盐脱酶 (G6PD) 缺乏影响全球4亿人,导致血液溶解和肝脏功能障碍.
- 患有G6PD缺乏症的个体表现出对病毒感染的敏感性增加.
- G6PD 缺乏对肝炎E 病毒 (HEV) 感染的具体影响在很大程度上仍未被描述.
研究的目的:
- 调查G6PD缺乏症患者中HEV感染的患病率和特征.
- 阐明G6PD缺陷个体中HEV易感性和疾病严重程度的潜在机制.
主要方法:
- 患病率研究,比较G6PD缺乏患者和对照患者的HEV感染率.
- 在体外实验中使用具有G6PD敲击的肝瘤细胞系来评估HEV易感性的实验.
- 分子测定包括共免疫沉 (Co-IP) 和同色定位,以分析G6PD和HEV相互作用.
主要成果:
- 在G6PD缺乏患者 (23.8%) 中,HEV感染的患病率明显高于正常G6PD水平 (0.65%) 的患者 (23.8%).
- 在HEV感染患者中,G6PD缺乏与高白血症和肺炎的增加率有关.
- G6PD的淘汰促进了HEV的进入,加剧了氧化应激,并促进了病毒复制,HEV ORF3与G6PD相互作用.
结论:
- 患有G6PD缺乏症的患者显然容易感染HEV.
- 促进HEV进入和增加氧化应激是导致HEV易感性和G6PD缺陷个体严重后果的关键因素.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
200
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
200
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
236
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
236
Energy-requiring Steps of Glycolysis
171.1K
Glucose is the source of nearly all energy used by organisms. The first step of converting glucose into usable energy is called glycolysis. Glycolysis occurs in the cytosol of the cell over two phases: an energy-requiring phase and an energy-releasing phase. Over the first three steps, glucose is converted into different forms and attached to two phosphate groups donated by two ATP molecules, resulting in an unstable sugar. In the next two stages, the unstable sugar splits into two sugar...
171.1K
Other Glycolytic Pathways
781
The pentose phosphate pathway (PPP) operates in parallel with glycolysis, facilitating the metabolism of both pentoses and glucose. This pathway consists of two distinct phases: the oxidative and non-oxidative phases. While it does not directly generate ATP, the intermediates formed during the process can integrate into glycolysis, contributing to cellular energy metabolism when required.Oxidative Phase: NADPH ProductionThe oxidative phase of the pentose phosphate pathway is primarily...
781
Glycolysis: Preparatory Phase
16.4K
In cellular metabolism (the complete breakdown of glucose to extract energy), glycolysis is the first step. Glycolysis takes place in the cytoplasm of both prokaryotic and eukaryotic cells. Glucose enters heterotrophic cells in two ways. One method is through secondary active transport, where the transport takes place against the glucose concentration gradient. The other mechanism uses a group of integral proteins called GLUT proteins, also known as glucose transporter proteins. These...
16.4K


